DK0719340T3 - Klonet glutaminsyre-decarboxylase - Google Patents

Klonet glutaminsyre-decarboxylase

Info

Publication number
DK0719340T3
DK0719340T3 DK94927940T DK94927940T DK0719340T3 DK 0719340 T3 DK0719340 T3 DK 0719340T3 DK 94927940 T DK94927940 T DK 94927940T DK 94927940 T DK94927940 T DK 94927940T DK 0719340 T3 DK0719340 T3 DK 0719340T3
Authority
DK
Denmark
Prior art keywords
glutamic acid
acid decarboxylase
cloned
cloned glutamic
gad
Prior art date
Application number
DK94927940T
Other languages
English (en)
Inventor
Allan J Tobin
Mark G Erlander
Daniel L Kaufman
Michael J Clare-Salzler
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0719340T3 publication Critical patent/DK0719340T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
DK94927940T 1993-09-17 1994-08-24 Klonet glutaminsyre-decarboxylase DK0719340T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/123,859 US5674978A (en) 1990-09-21 1993-09-17 Peptides derived from glutamic acid decarboxylase
PCT/US1994/009478 WO1995007992A2 (en) 1993-09-17 1994-08-24 Cloned glutamic acid decarboxylase

Publications (1)

Publication Number Publication Date
DK0719340T3 true DK0719340T3 (da) 2002-11-18

Family

ID=22411325

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94927940T DK0719340T3 (da) 1993-09-17 1994-08-24 Klonet glutaminsyre-decarboxylase

Country Status (11)

Country Link
US (5) US5674978A (da)
EP (1) EP0719340B1 (da)
JP (1) JP3133339B2 (da)
KR (1) KR100367943B1 (da)
AT (1) ATE221125T1 (da)
AU (1) AU697058B2 (da)
CA (1) CA2170523C (da)
DE (1) DE69431060T2 (da)
DK (1) DK0719340T3 (da)
ES (1) ES2179077T3 (da)
WO (1) WO1995007992A2 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8721991A (en) 1990-09-07 1992-03-30 Regents Of The University Of California, The Methods for the diagnosis and treatment of diabetes
US6682906B1 (en) * 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
CA2103159A1 (en) * 1991-05-15 1992-11-16 Ake Lernmark Cloning and expression of human islet glutamic acid decarboxylase autoantigen
EP0701569B1 (en) * 1992-12-03 2008-11-12 The Regents Of The University Of California Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
CA2140591A1 (en) * 1994-01-20 1995-07-21 Josef Endl Antigen-specific, activated t lymphocytes, detection and use
EP0815136B1 (en) * 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5945401A (en) * 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
DE19526561A1 (de) * 1995-07-20 1997-01-23 Boehringer Mannheim Gmbh In-vivo-Diabetes-Test
EP0923944A4 (en) * 1996-04-01 2000-05-03 Chugai Pharmaceutical Co Ltd DIAGNOSTIC COMPOSITION FOR DISEASES ACCOMPANIED BY AUTO-IMMUNE REACTIONS TRIGGERED BY 65K-GLUTAMIC ACID DECARBOXYLASE
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6815174B1 (en) * 1996-11-28 2004-11-09 Edgardo Poskus Thioredoxin-glutamate decarboxylase 65 fusion protein
FR2759701B1 (fr) * 1997-02-19 1999-06-04 Inst Nat Sante Rech Med Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
CA2306953A1 (en) * 1997-10-17 1999-04-29 Abd Al-Roof Higazi Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
SE9704451D0 (sv) * 1997-11-28 1997-11-28 Diamyd Therapeutics Ab New method and compositions for the treatment of autoimmune diseases
AU2566799A (en) * 1998-01-27 1999-08-09 Jane Pei-Fan Bai Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
AU775484C (en) * 1999-08-23 2005-02-17 Benaroya Research Institute At Virginia Mason Peptide and peptide analogues for the treatment and prevention of diabetes
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
EP1149914B1 (de) * 2000-04-10 2008-06-18 Labor Dr. Merk und Kollegen GmbH Fusionsprotein zur gleichzeitigen Erkennung von humanen Autoantikörpern
JP2003532078A (ja) 2000-04-19 2003-10-28 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 子宮内膜症の診断アッセイ
US7178152B2 (en) * 2001-03-01 2007-02-13 Sony Corporation Application programming interface for communication between audio/video file system and audio video controller
CA2443777A1 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
US20050130245A1 (en) * 2001-09-17 2005-06-16 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
WO2005102374A2 (en) * 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
WO2007114959A2 (en) * 2006-04-04 2007-10-11 University Of Toledo Altered peptide ligands of gad65
CN100450552C (zh) * 2006-05-26 2009-01-14 中国医学科学院医学生物学研究所 Ⅰ型糖尿病疫苗及其构建方法
US20090098631A1 (en) * 2006-08-01 2009-04-16 Neurologix, Inc. Novel glutamic acid decarboxylase (GAD) proteins and methods of use
US20100279422A1 (en) * 2006-08-21 2010-11-04 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) technology to detect genomic disorders for prenatal diagnosis
WO2008036465A2 (en) * 2006-09-18 2008-03-27 CMED Technologies Ltd. Office of Walkers Limited A method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors
WO2008036470A2 (en) * 2006-09-19 2008-03-27 Cmed Technologies Ltd. A method for screening of infectious agents in blood
US20100047815A1 (en) * 2006-09-21 2010-02-25 Cmed Technologies Ltd. Method to detect tumor markers and diagnosis of undifferentiated tumors
WO2008070223A2 (en) * 2006-09-21 2008-06-12 Cmed Technologies Ltd. A method to remove repetitive sequences from human dna
WO2008082710A2 (en) * 2006-09-25 2008-07-10 Cmed Technologies Ltd. A method of surface plasmon resonance (spr) technology to detect genomic aberrations in patients with multiple myeloma
GB2455929B (en) * 2006-09-25 2011-08-31 Cmed Technologies Limited A method for the identification of human immunodeficiency virus related antibodies in blood
US20090311699A1 (en) * 2006-09-25 2009-12-17 Cmed Technologies Ltd. Method of surface plasmon resonance (spr) to detect genomic aberrations in patients with chronic lymphocytic leukemia
US20100028856A1 (en) * 2006-09-25 2010-02-04 Cmed Technologies Ltd. Method to detect virus related immunological markers for the diagnosis of hepatitis b virus infection
WO2008094312A2 (en) * 2006-09-25 2008-08-07 Cmed Technologies Ltd. A method of surface plasmon resonance (spr) technology to detect genomic disorders for postnatal diagnosis
US20100041018A1 (en) * 2006-09-25 2010-02-18 Cmed Technologies Ltd. Method to detect virus related immunological markers for the diagnosis of hepatitis c virus infection
WO2008070241A2 (en) * 2006-09-27 2008-06-12 Cmed Technologies Ltd. A method to measure serum biomarkers for the diagnosis of liver fibrosis
WO2008067008A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. A method for the quantitative evaluation of sex hormones in a serum sample
US20100004872A1 (en) * 2006-09-27 2010-01-07 Cmed Technologies Ltd. Method for quantitative measurement of cardiac biochemical markers
WO2008066994A2 (en) * 2006-09-27 2008-06-05 Cmed Technologies Ltd. Application of surface plasmon resonance technology to maternal serum screening for congenital birth defects
US8158343B2 (en) * 2006-09-27 2012-04-17 Cmed Technologies Ltd. Method to detect virus related immunological markers for the diagnosis of respiratory tract infections
US20100086937A1 (en) * 2006-09-27 2010-04-08 Cmed Technologies Ltd. method to detect treponema pallidum immunological markers for the diagnosis of syphilis
US8110408B2 (en) * 2006-09-28 2012-02-07 Cmed Technologies Ltd. Method for quantitative detection of diabetes related immunological markers
WO2008067007A2 (en) * 2006-09-28 2008-06-05 Cmed Technologies Ltd. A method for quantitative measurement of thyroid homrones and related antibodies in a serum sample
WO2008111634A1 (ja) * 2007-03-15 2008-09-18 Reverse Proteomics Research Institute Co., Ltd. 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
EP2137315B1 (en) 2007-03-16 2014-09-03 Genomatica, Inc. Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors
US20090092637A1 (en) * 2007-04-24 2009-04-09 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
US7947483B2 (en) 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
WO2009045216A1 (en) 2007-10-04 2009-04-09 Cmed Technologies Ltd. Application of surface plasmon resonance technology for detecting and genotyping hpv
EP3514242A3 (en) 2008-09-10 2019-08-28 Genomatica, Inc. Microrganisms for the production of 1,4-butanediol
EP3269379A1 (en) 2008-11-30 2018-01-17 Immusant, Inc. Compositions and methods for treatment of celiac disease
VN29801A1 (da) 2009-06-04 2012-05-25
SI3199511T1 (sl) 2009-06-04 2020-07-31 Genomatica, Inc. Proces separacije komponent fermentacijske brozge
KR20120083908A (ko) * 2009-10-13 2012-07-26 게노마티카 인코포레이티드 1,4-부탄다이올, 4-하이드록시부탄알, 4-하이드록시부티릴-ｃｏａ, 푸트레신 및 관련 화합물의 제조를 위한 미생물 및 관련 방법
WO2011066076A1 (en) 2009-11-25 2011-06-03 Genomatica, Inc. Microorganisms and methods for the coproduction of 1,4-butanediol and gamma-butyrolactone
US8048661B2 (en) 2010-02-23 2011-11-01 Genomatica, Inc. Microbial organisms comprising exogenous nucleic acids encoding reductive TCA pathway enzymes
US8637286B2 (en) 2010-02-23 2014-01-28 Genomatica, Inc. Methods for increasing product yields
EP2836845B1 (en) 2012-04-13 2018-05-09 DiabetOmics, Inc. Maternal biomarkers for gestational diabetes
WO2013184602A2 (en) 2012-06-04 2013-12-12 Genomatica, Inc. Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
DK3151853T3 (da) * 2014-06-04 2020-07-27 Diamyd Medical Ab Glutaminsyre-decarboxylase (GAD) til anvendelse ved behandling af en autoimmun sygdom
US10370718B2 (en) 2014-09-29 2019-08-06 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
EP3221344A2 (en) 2014-11-21 2017-09-27 Immusant Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
TWI655812B (zh) 2016-07-20 2019-04-01 松下知識產權經營股份有限公司 懸吊型插座
GB202210967D0 (en) * 2022-07-27 2022-09-07 Univ Birmingham Tolerogenic peptides i

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4487830A (en) * 1982-05-14 1984-12-11 American Hoechst Corporation Enzyme/immunofluorescent assay for autoantibodies
EP0138854B1 (en) * 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1990007117A1 (en) * 1988-12-13 1990-06-28 University Of Florida Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
NO306996B1 (no) * 1989-02-17 2000-01-24 Bayer Ag Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
DE69122761T2 (de) * 1990-08-17 1997-03-13 Univ Florida Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5475086A (en) * 1990-09-21 1995-12-12 The Regents Of The University Of California Cloned glutamic acid decarboxylase peptides
AU8864791A (en) * 1990-10-02 1992-04-28 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
WO1992014485A1 (en) * 1991-02-22 1992-09-03 Amrad Corporation Limited A method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases
CA2103159A1 (en) * 1991-05-15 1992-11-16 Ake Lernmark Cloning and expression of human islet glutamic acid decarboxylase autoantigen
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
SG49008A1 (en) * 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US5547847A (en) * 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes

Also Published As

Publication number Publication date
KR100367943B1 (ko) 2003-06-18
CA2170523C (en) 2010-03-30
ES2179077T3 (es) 2003-01-16
JP3133339B2 (ja) 2001-02-05
EP0719340B1 (en) 2002-07-24
ATE221125T1 (de) 2002-08-15
US6011139A (en) 2000-01-04
AU7920194A (en) 1995-04-03
JPH09503387A (ja) 1997-04-08
US5674978A (en) 1997-10-07
CA2170523A1 (en) 1995-03-23
DE69431060T2 (de) 2002-11-14
DE69431060D1 (de) 2002-08-29
WO1995007992A2 (en) 1995-03-23
US8926966B1 (en) 2015-01-06
KR960705051A (ko) 1996-10-09
EP0719340A1 (en) 1996-07-03
US6455267B1 (en) 2002-09-24
US5846740A (en) 1998-12-08
AU697058B2 (en) 1998-09-24
WO1995007992A3 (en) 1995-06-22

Similar Documents

Publication Publication Date Title
DE69431060T2 (de) Klonierte glutaminsäure-decarboxylase
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
EA199800946A1 (ru) Концентрированный препарат антител
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
GB2367061A (en) Peptides
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
ES2177625T3 (es) Citoquina cc-1 humana circulante.
DE68917837D1 (de) Peptid-Verbindungen.
AU1086888A (en) Primary biliary cirrhosis autoantigen
DK1431391T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DE3650035D1 (de) THF-Zusammensetzungen.
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
EP0317279A3 (en) Peptides for use in the purification of factor viii
DE68914397D1 (de) Menschliches Lymphotoxin.
MX9800239A (es) Metodos para el tratamiento y prevencion de diabetes.